Our investments accelerate growth and stimulate private sector innovation and investment, giving our partners additional tools to effect change and improve lives. We make investments that align with foundation issue areas from vaccine development to education in the United States.
More on the types of investments we make.
Here you can explore our current and past investments, filtered by issue area or investment type.
Achaogen is focused on R&D and commercialization of antibacterials to combat multi-drug resistant, Gram-negative infections. The foundation’s investment is supporting the development of Achaogen’s monoclonal antibody (“mAb”) discovery platform.
Press Release
Affinivax achieves unprecedented levels of immune response and disease protection by streamlining the process of vaccine design and allowing for multiple antigens to be effectively incorporated in a single vaccine.
News Story
The foundation invested in Amyris to support the development of new, low-cost technologies for manufacturing compounds to make semi-synthetic artemisinin that can be used in anti-malaria treatments.
Anacor Pharmaceuticals developed and commercialized novel therapeutics with its boron chemistry platform. The foundation partnered with the team to support development of preclinical drug candidates.
Press Release
Arsanis is focused on discovery and development of novel monoclonal antibodies (“mAbs”) to prevent and treat infectious disease. The foundation is working with Arsanis to develop a prophylactic mAb candidate targeting Stap aureus, a leading cause of neonatal sepsis which leads to approximately 345,000 annual deaths globally.
Press Release
Atreca is a biotechnology company that employs its proprietary discovery platform to generate and develop therapeutics based on its ability to rapidly characterize the human adaptive immune response at the single cell level. The Atreca platform enables the high-throughput phylogenetic Read More
News Story
Aurobindo Pharma, along with Mylan Laboratories, received support from the foundation to expand the distribution of a single-pill HIV treatment containing dolutegravir to low- and middle-income populations at a low price.
Press Release
Butterfly has created the world’s first handheld whole body ultrasound system to democratize healthcare and provide global access to medical imaging. The device is critical to the foundation’s vision of an ecosystem where hardware, software, data and expertise come together Read More
Press Release
The foundation invested in CureVac to accelerate vaccine technology development, getting life-saving and low-cost vaccines to people who need them most.
Press Release
Evolve BioSystems is an infant microbiome company dedicated to developing the next generation of products to establish, restore and maintain a healthy gut microbiome. The foundation is working with Evolve to further develop and apply its lead probiotic, Evivo, to Read More
Press Release